Oct 09 2026 09:13 PM EST
Argenx Shares Fall After Sjögren’s Trial Halt and Mixed Clinical News
Argenx SE (NASDAQ:ARGX) fell more than 12% in the last five trading sessions, a move that coincided with the abrupt termination of its Phase 3 UNITY trial in Sjögren’s disease and a mixed set of clinical read‑outs, even as the company posted a robust Q2 earnings beat and expanded the label of its flagship product VYVGART.
The stock opened at $818.63, below its 50‑day moving average of $960.50 and its 200‑day average of $876.48. Over the five‑day window the share price declined 12.5%, marking the steepest slide since the company’s 2025 surge.
Quarterly Results Reinforce Strong Growth Trend
In the quarter ended 30 Jun 2026, argenx reported product net sales of $1.52 billion, up 60% YoY and 17% QoQ. Operating profit rose to $494 million (a 146% YoY increase) and net profit reached $472 million. Basic EPS of $7.58 beat consensus estimates by roughly 18%.
Cash, cash equivalents and current financial assets grew to $5.2 billion, an increase of $744 million from the start of 2026, providing ample liquidity to fund ongoing trials and commercial roll‑outs.
Clinical Catalyst: UNITY Halt Triggers Immediate Sell‑off
On 8 Oct 2026 the independent data‑monitoring committee recommended stopping the Phase 3 UNITY trial of subcutaneous efgartigimod in Sjögren’s disease for futility. The announcement sent the stock down more than 14% in pre‑market trading, accounting for a large portion of the five‑day decline.
Investors interpreted the halt as a setback to argenx’s strategy of expanding its FcRn‑blocking platform beyond generalized myasthenia gravis (gMG). While safety remained acceptable, the lack of efficacy undermines the company’s goal of securing ten labeled indications by 2030.
Other Pipeline Highlights Offer Mixed Signals
The same day, argenx announced positive topline data from its Phase 2 FB102 study in celiac disease, meeting its primary endpoint (p = 0.0176) and receiving FDA Fast‑Track designation, which could progress to Phase 3. Conversely, the Phase 3 ALKIVIA trial in autoimmune myositis reported a 15.4‑point improvement in Total Improvement Score versus placebo, a promising signal but still early in development.
The company also expects to start Phase 2 testing of ARGX‑121 (IgA nephropathy) and Phase 1 entry for several next‑generation FcRn candidates later in 2026, keeping the pipeline active despite the UNITY disappointment.
Macro and Sector Context
Biotech equities remain sensitive to interest‑rate expectations and inflation trends. Recent hopes for rate cuts have provided modest tailwinds, yet heightened volatility persists across the sector. In addition, U.S. tariffs on branded drugs—potentially reaching 100%—create supply‑chain uncertainty for firms without domestic manufacturing footprints, a factor that could affect argenx’s cost structure and pricing strategy.
Analyst Sentiment and Valuation
Despite the recent sell‑off, consensus analyst coverage remains bullish, with an average 12‑month price target of €1,048.83 versus the current price of €728.40, implying roughly 44% upside. UBS upgraded the stock to “Buy” and raised its target to $1,400, while Baird cut its target to $823, reflecting divergent views on the impact of the UNITY halt.
The company trades at a forward P/E of about 31.4 and a PEG of 0.97, suggesting valuation is still anchored to continued revenue expansion from VYVGART and future indications.
Risks and Open Questions
Key risks include the potential for further trial failures in late‑stage programs, continued reliance on the FcRn franchise, and the impact of U.S. drug‑tariff policies on pricing and margins. The short interest of roughly 2.2% indicates some speculative pressure, while the upcoming earnings release on 22 Oct 2026 will test whether the strong Q2 performance can be sustained amid a more challenging pipeline narrative.
Investors will be watching for guidance on the next‑generation FcRn candidates, the commercial rollout of VYVGART SC, and any regulatory updates that could reshape the revenue outlook before the end of 2026.